Journal Article Ppublish 25 citations
PubMed: 34222852 DOI: 10.1016/j.metop.2021.100103
Roles of existing drug and drug targets for COVID-19 management.
Metabol Open 11:100103
Authors: Akeberegn Gorems Ayele, Engidaw Fentahun Enyew, Zemene Demelash Kifle
Affiliations
- Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia.
- Department of Human Anatomy, School of Medicine, College of Medicine and Health Sciences, Gondar, Ethiopia.
- Department of Pharmacology, School of Pharmacy, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Abstract
In December 2019, a highly transmissible, pneumonia epidemic caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), erupted in China and other countries, resulting in devastation and health crisis worldwide currently. The search and using existing drugs support to curb the current highly contagious viral infection is spirally increasing since the pandemic began. This is based on these drugs had against other related RNA-viruses such as MERS-Cov, and SARS-Cov. Moreover, researchers are scrambling to identify novel drug targets and discover novel therapeutic options to vanquish the current pandemic. Since there is no definitive treatment to control Covid-19 vaccines are remain to be a lifeline. Currently, many vaccine candidates are being developed with most of them are reported to have positive results. Therapeutic targets such as helicases, transmembrane serine protease 2, cathepsin L, cyclin G-associated kinase, adaptor-associated kinase 1, two-pore channel, viral virulence factors, 3-chymotrypsin-like protease, suppression of excessive inflammatory response, inhibition of viral membrane, nucleocapsid, envelope, and accessory proteins, and inhibition of endocytosis were identified as a potential target against COVID-19 infection. This review also summarizes plant-based medicines for the treatment of COVID-19 such as and some others. Thus, this review aimed to focus on the most promising therapeutic targets being repurposed against COVID-19 and viral elements that are used in COVID-19 vaccine candidates.
MeSH
Infections, Membranes, Pharmaceutical Preparations, Therapeutics, Rna Viruses, Coronavirus, Chymases, Pandemics, Sars-Cov-2, Covid-19 Vaccines
Cited by
- Current status and future challenges in extraction, purification and identification of Cepharanthine (a potential drug against COVID-19). Sep Purif Technol, 2023
- The Potential of Usnic-Acid-Based Thiazolo-Thiophenes as Inhibitors of the Main Protease of SARS-CoV-2 Viruses. Viruses, 2024
- Structural basis for inhibition of the lysosomal two-pore channel TPC2 by a small molecule antagonist. Structure, 2024
- Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial : Author detials. Sci Rep, 2025
- Analytical approaches for determination of COVID-19 candidate drugs in human biological matrices. Trends Analyt Chem, 2023
- Perspectives in vaccines, immune response, therapeutic interventions and COVID-19. Metabol Open, 2022
- Cepharanthine loaded nanoparticles coated with macrophage membranes for lung inflammation therapy. Drug Deliv, 2022
- Diabetes and COVID-19: Mechanism of pneumonia, treatment strategy and vaccine. Metabol Open, 2021
- Targeting the receptor binding domain and heparan sulfate binding for antiviral drug development against SARS-CoV-2 variants. Sci Rep, 2024